Jessica Hergert

Articles

New Designations and Efficacy Demonstrations Push the EGFR+ NSCLC Paradigm Forward

January 20th 2021

Timothy F. Burns, MD, PhD, dissects the role of osimertinib in EGFR-mutant NSCLC, sheds light on remaining questions in the field, and speaks to some of the most intriguing emerging agents in the space.

High-Dose Y-90 Pushes the HCC Paradigm Toward Personalized, Multidisciplinary Care

January 20th 2021

Beau Toskich, MD, discusses the potential of TheraSphere as a therapy in hepatocellular carcinoma, the importance of utilizing a multidisciplinary approach among novel radiation oncology agents, and his hope for a future prospective clinical trial evaluating Y-90.

Remaining ECHELON-2 Questions Spark Novel Research Efforts in PTCL

January 19th 2021

Jakub Svoboda, MD, discusses the results of the ECHELON-2 trial and explained where clinical research is headed in peripheral T-cell lymphoma.

Second-Line Pembrolizumab Has Maintained Survival Benefit in Advanced HCC

January 18th 2021

January 17, 2021 - Pembrolizumab demonstrated maintained numerical improvements in overall survival and progression-free survival compared with placebo in patients with previously treated advanced hepatocellular carcinoma.

CLL Paradigm Poised to Expand With Novel Therapies as Chemo Is Phased Out

January 13th 2021

James Gerson, MD, discusses how he navigates treatment selection for patients with chronic lymphocytic leukemia and exciting developments in the pipeline.

Fleshing Out HER2-Directed Therapies in GI Malignancies

January 11th 2021

The field of HER2-positive gastrointestinal malignancies witnessed a surge of data in 2020 regarding investigational agents, such as the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki, that could play a pivotal role in transforming treatment selection in the coming years.

Navigating Nuances in Early and Metastatic Lung Cancer Treatment

January 7th 2021

Brendon Stiles, MD, discusses his approach to treating patients with early-stage and metastatic lung cancer, the importance of molecular testing and screening, and remaining challenges in the space.

MCL Landscape Adapts to Changes After CAR T-Cell Therapy Approval

January 6th 2021

James Gerson, MD, discusses the introduction of CAR T-cell therapy to the mantle cell lymphoma armamentarium and how induction therapy followed by stem cell transplant has maintained a role.

Updated ExteNET Data Raise Questions Over TKI Utility in HER2+ Breast Cancer Brain Metastases and the Future of Neratinib

January 6th 2021

Adam M. Brufsky, MD, PhD, discusses the updated findings from the ExteNET trial, the role of TKIs in treating patients with brain metastases, and unanswered questions that future research efforts should aim to address.

Novel CDK4/6 Inhibitor ON 123300 Receives Green Light to Move Into Phase 1 Testing in Relapsed/Refractory Advanced Cancers

January 5th 2021

January 5, 2021 – The FDA has granted permission for a phase 1 study evaluating ON 123300, a first-in-class multikinase CDK4/6 inhibitor to proceed under the agent’s investigational new drug application.

x